{
    "id": 14822,
    "fullName": "GRM3 positive",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "GRM3 positive indicates the presence of the GRM3 gene, mRNA, and/or protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 2913,
        "geneSymbol": "GRM3",
        "terms": [
            "GRM3",
            "GLUR3",
            "GPRC1C",
            "mGlu3",
            "MGLUR3"
        ]
    },
    "variant": "positive",
    "createDate": "12/07/2015",
    "updateDate": "07/31/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 17687,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, malignant glioma cells expressing GRM3 demonstrated decreased cell growth and MAPK pathway activation in culture and reduced tumor size in cell line xenograft models when treated with LY341495 (PMID: 16053698).",
            "molecularProfile": {
                "id": 15081,
                "profileName": "GRM3 positive"
            },
            "therapy": {
                "id": 3267,
                "therapyName": "LY341495",
                "synonyms": null
            },
            "indication": {
                "id": 3070,
                "name": "malignant glioma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4064,
                    "pubMedId": 16053698,
                    "title": "Pharmacological blockade of group II metabotropic glutamate receptors reduces the growth of glioma cells in vivo.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/16053698"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 15081,
            "profileName": "GRM3 positive",
            "profileTreatmentApproaches": [
                {
                    "id": 7198,
                    "name": "LY341495",
                    "profileName": "GRM3 positive"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}